Imatinib-Resistant GIST

First-Line Imatinib More Effective Than Widely Believed – LRG Science

The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.

By |2020-05-01T09:56:32-04:00December 13th, 2019|Drug Treatment, Gleevec, LRG Science, News|

Mechanisms of Disease Persistence in Gastrointestinal Stromal Tumors

By Tamas Ordog, LRG Research Team, Martin Zörnig and Yujiro Hayashi Dr. Tamas Ordog Gastrointestinal stromal tumors (GIST) represent a substantial proportion of human bone and soft tissue sarcomas.1 GIST are thought [...]

By |2019-10-31T12:01:09-04:00October 16th, 2015|News, Research|

Update on Potential Treatments for Imatinib-Resistant GIST

In a recent article entitled "Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions" published online in Springer for Research and Development,  LRG Research Team member Sebastian Bauer [...]

By |2019-10-31T12:01:30-04:00July 31st, 2015|News, Research|
Go to Top